Abstract:Alzheimer's disease (AD), the most common disabling impairment in older adults, takes an unacceptable toll on patients and families. With the growing number of people living to older ages, it is projected to afflict more than 100 million people around the world by 2050. While there is an urgent need, it takes too many cognitively normal (CN) individuals and too many years to evaluate presymptomatic AD treatments using traditional clinical endpoints. We and our colleagues have been using imaging techniques to detect the brain changes associated with the predisposition to AD in CN individuals with 2, 1 and 0 copies of the apolipoprotein E (APOE) e4 allele, the major late-onset AD susceptibility gene, and in CN presenilin 1 (PSEN1) mutation carriers and non-carriers from the world’s largest autosomal dominant early-onset AD kindred in Antioquia, Colombia; we developed several image-analysis techniques and a composite cognitive measure with improved power; and we estimated the sample sizes needed when using these endpoints. We recently proposed the Alzheimer’s Prevention Initiative (API) to help in the effort to launch an era in AD prevention research. The API will include preclinical AD treatment/biomarker development trials in individuals at increased genetic risk for early-onset and late-onset AD, an extremely large Colombian early-onset AD Prevention Registry; and an extremely large North American Alzheimer’s Prevention Registry to support several preclinical AD trials. The API’s first trial will test the anti-amyloid immunization therapy crenezumab in CN PSEN1 mutation carriers using the best established brain imaging and cerebrospinal fluid measurements and our composite cognitive measure as the primary clinical endpoint. It is intended to test an anti-amyloid agent in the preclinical treatment of AD, help determine the extent to which a treatment’s biomarker effects predict a clinical outcome, provide a better test of the amyloid hypothesis, and provide raw data and biological samples to the research community. With support from the U.S. National Institutes of Health, philanthropic funds from the Banner Alzheimer’s Institute, and Genentech, it is also intended to help provide a new paradigm for research collaboration in clinical trials. In this presentation, we will briefly introduce the crucial role of flourodeoxyglucose positron emission tomography (PET), amyloid PET, structural and functional MRI in the preclinical detection, tracking, and treatment of AD. We will present the novel image processing methods we have developed to help in this endeavor, as well as their implementation in the API’s preclinical treatment/biomarker development programs.

Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease

Alzheimer's Disease Clinical Trials: What Have We Learned From Magnetic Resonance Imaging

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease

Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)

Brain imaging in the study of Alzheimer's disease

Brain Imaging Biomarkers for the Alzheimer’s Prevention Initiative

Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring

Recent Advances in Neuroimaging Techniques to Assist Clinical Trials on Cell-Based Therapies in Neurodegenerative Diseases

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

Functional Magnetic Resonance Imaging in Alzheimer's Disease Drug Trials: A Mini-Review

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Detection and treatment of Alzheimer’s disease in its preclinical stage

Neuroimaging techniques, gene therapy, and gut microbiota: frontier advances and integrated applications in Alzheimer's Disease research

Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging

Positron Emission Tomography/Computed Tomography Imaging in Therapeutic Clinical Trials in Alzheimer's Disease: An Overview of the Current State of the Art of Research

Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease

Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies

P4–066: Alzheimer's Disease Biomarkers As Outcome Measures for Clinical Trials